Amarin Corp Plcuk (AMRN) Accumulated Expenses (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Accumulated Expenses of $145.4 million for Q2 2026, up 2.95% year-over-year from $141.2 million in Q2 2025, and up 10.58% quarter-over-quarter from $131.5 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Accumulated Expenses (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Accumulated Expenses for 17 consecutive years, with $145.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Accumulated Expenses rose 2.95% year-over-year to $145.4 million; the TTM figure through Jun 2026 stood at $145.4 million (up 2.95% YoY), while the FY2025 annual figure was $149.1 million, up 6.82% from the prior year.
- Accumulated Expenses improved to $145.4 million in Q2 2026 per AMRN's latest filing, from $131.5 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $243.1 million in Q2 2022 and bottomed at $116.7 million in Q1 2025.
- Historically, Accumulated Expenses has averaged $172.7 million across 5 years, with a median of $168.6 million in 2024.
- Annual changes were most pronounced in 2022 — Accumulated Expenses plunged 33.72% — and 2026, when it grew 12.63%.
- Amarin Corp Plc\Uk's Accumulated Expenses stood at $192.7 million in 2022, then increased by 5.97% to $204.2 million in 2023, then sank by 31.64% to $139.6 million in 2024, then rose by 6.82% to $149.1 million in 2025, then declined by 2.48% to $145.4 million in 2026.
- Business Quant data shows AMRN's Accumulated Expenses at $145.4 million in Q2 2026, $131.5 million in Q1 2026, and $149.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 145.40 Mn |
| Mar 31, 2026 | 131.49 Mn |
| Dec 31, 2025 | 149.10 Mn |
| Sep 30, 2025 | 145.52 Mn |
| Jun 30, 2025 | 141.24 Mn |
| Mar 31, 2025 | 116.75 Mn |
| Dec 31, 2024 | 139.58 Mn |
| Sep 30, 2024 | 161.05 Mn |
| Jun 30, 2024 | 176.16 Mn |
| Mar 31, 2024 | 154.44 Mn |
| Dec 31, 2023 | 204.17 Mn |
| Sep 30, 2023 | 211.30 Mn |
| Jun 30, 2023 | 214.60 Mn |
| Mar 31, 2023 | 183.26 Mn |
| Dec 31, 2022 | 192.68 Mn |
| Sep 30, 2022 | 192.00 Mn |
| Jun 30, 2022 | 243.06 Mn |
| Mar 31, 2022 | 207.62 Mn |
| Dec 31, 2021 | 253.11 Mn |
| Sep 30, 2021 | 289.68 Mn |